CTLA4 and Autoimmunity: Although current methods of immunotherapy in cancer are largely based on the use of the immune checkpoint inhibitors anti-CTLA-4 and anti-PD-1 antibodies, the major obstacle resides in opportunistic autoimmune disorders and associated morbidity resulting from altered immune regulation (88, 89).